Jump to content

Cytokine adsorbing column

From Wikipedia, the free encyclopedia

Cytokine-adsorbing columns remove inflammatory toxins from the body.[1] Such technology is currently being studied in more than 53 countries, including to treat sepsis in the European Union.[1][2] Specific products include the brand names Cytosorb by Cytosorbents, Lixelle among others.[1]

Their use is currently experimental; early clinical trials have generally failed to show significant improvement in survival.

Using cytokine-adsorbing columns involves channeling the patient's blood through a cartridge containing millions of minuscule polymer beads which trap toxins and inflammatory proteins. For this reason, the technology can only be used in conjunction with an additional blood pump system, like a dialysis machine or a heart-lung machine.[2]

When cytokine-adsorbing columns are used in patients with septic shock, their additional clearance of antibiotics and antifungals should be taken into account, in order to increase their dose, especially when lipophilic anti-infective agents are administered.[3]

The US Air Force is funding a $3 million FDA approved randomized controlled trial in trauma and rhabdomyolysis.[4][5]

References

[edit]
  1. ^ a b c Honore, PM; Jacobs, R; Joannes-Boyau, O; De Regt, J; De Waele, E; van Gorp, V; Boer, W; Verfaillie, L; Spapen, HD (2013). "Newly designed CRRT membranes for sepsis and SIRS--a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review". ASAIO Journal. 59 (2): 99–106. doi:10.1097/mat.0b013e3182816a75. PMID 23438770. S2CID 21246431.
  2. ^ a b "This Cartridge of Plastic Beads Can Filter Blood During Surgery". Bloomberg. 10 September 2018. Retrieved 2018-09-10.
  3. ^ Berlot, Giorgio; Di Bella, Stefano; Tomasini, Ariella; Roman-Pognuz, Erik (2022-01-29). "The Effects of Hemoadsorption on the Kinetics of Antibacterial and Antifungal Agents". Antibiotics. 11 (2): 180. doi:10.3390/antibiotics11020180. hdl:11368/3007260. ISSN 2079-6382. PMC 8868360. PMID 35203783.
  4. ^ "Biotech Product Geared Toward Reducing Deaths in the ICU". Sentinel. Archived from the original on 7 June 2014. Retrieved 9 April 2014.
  5. ^ "Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis". clinicaltrials.gov. Retrieved 6 May 2014.